Trial Profile

A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin vs SoC for the Treatment of Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oritavancin (Primary) ; Cefazolin; Ceftaroline fosamil; Clindamycin; Cloxacillin; Nafcillin; Oxacillin; Teicoplanin; Vancomycin
Indications Bacterial skin diseases
Focus Adverse reactions
Sponsors Melinta Therapeutics

15 Feb 2024 Planned End Date changed from 15 Dec 2025 to 15 Jan 2026.
04 May 2023 Status changed from not yet recruiting to recruiting.
13 Jan 2023 Planned initiation date changed from 31 Oct 2022 to 31 Mar 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com